Lotus Pharmaceuticals (LTUS) Ratios
Lotus Pharmaceuticals Ratios
LTUS's free cash flow for Q2 2024 was $-3.85K. For the 2024 fiscal year, LTUS's free cash flow was increased by $0.00 and operating cash flow was $-3.85K. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.05 | 0.05 | 0.10 | 0.04 | 0.00 |
| Quick Ratio | 0.05 | 0.05 | 0.10 | 0.04 | 0.00 |
| Cash Ratio | 0.02 | 0.01 | 0.10 | 0.04 | 0.00 |
| Solvency Ratio | 1.28 | 2.14 | 2.73 | 5.09 | 4.94 |
| Operating Cash Flow Ratio | -0.16 | -0.25 | -0.40 | -0.16 | -0.72 |
| Short-Term Operating Cash Flow Coverage | -0.16 | -0.25 | -0.40 | -0.16 | -0.72 |
| Net Current Asset Value | $ -111.00K | $ -92.19K | $ -67.97K | $ -37.55K | $ -30.34K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 20.54 | 20.11 | 9.86 | 22.55 | 3.56 |
| Debt-to-Equity Ratio | -1.05 | -1.05 | -1.11 | -1.05 | -1.39 |
| Debt-to-Capital Ratio | 20.53 | 20.98 | 9.86 | 22.55 | 3.56 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.05 | -0.05 | -0.11 | -0.05 | -0.39 |
| Debt Service Coverage Ratio | -0.16 | -0.22 | -0.40 | -0.16 | -1.44 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -6.10 | -4.53 | -2.23 | -5.98 | -1.39 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| EBT Per EBIT | 100.01% | 99.99% | 100.01% | 100.05% | 0.00% |
| Return on Assets (ROA) | -331.14% | -438.56% | -396.52% | -360.47% | -255.61% |
| Return on Equity (ROE) | 16.95% | 22.90% | 44.75% | 16.73% | 100.00% |
| Return on Capital Employed (ROCE) | 16.95% | 22.90% | 44.74% | 16.72% | 100.00% |
| Return on Invested Capital (ROIC) | -331.10% | -457.62% | -396.48% | -360.30% | 0.00% |
| Return on Tangible Assets | -331.14% | -438.56% | -396.52% | -360.47% | -255.61% |
| Earnings Yield | -0.16% | -0.08% | -0.06% | -0.02% | -0.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.16 | -0.25 | -0.40 | -0.16 | -0.72 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -0.17% | -0.09% | -0.06% | -0.02% | -0.05% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -608.74 | -1276.54 | -1641.06 | -5155.13 | -1841.19 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -103.17 | -292.28 | -734.33 | -862.51 | -1841.19 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -598.56 | -1131.29 | -1641.06 | -5155.13 | -1841.19 |
| Price-to-Operating Cash Flow Ratio | -598.56 | -1131.29 | -1641.06 | -5155.13 | -1841.19 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | -614.91 | -1280.95 | -1643.46 | -5163.57 | -1842.58 |
| Enterprise Value | 11.57M | 27.04M | 49.98M | 32.43M | 40.22M |
| EV to EBITDA | -614.91 | -1280.95 | -1643.46 | -5163.57 | -1842.58 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -604.56 | -1135.31 | -1643.29 | -5161.11 | -1842.58 |
| EV to Operating Cash Flow | -604.56 | -1135.31 | -1643.29 | -5161.11 | -1842.58 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.02 | 1.13 | 1.00 | 1.00 | 1.00 |
Currency in USD
